We are live on ! Find out more
HOWL icon

Werewolf Therapeutics
HOWL

35 hedge funds and large institutions have $51.1M invested in Werewolf Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 4

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.55% less ownership

Funds ownership: 67.52% → 66.97% (-0.55%)

3% less funds holding

Funds holding: 36 → 35 (-1)

30% less capital invested

Capital invested by funds: $73.3M → $51.1M (-$22.2M)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $7K

Holders
35
Holders Change
-1
Holders Change %
-2.78%
% of All Funds
0.56%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
2
Increased
11
Reduced
4
Closed
3
Calls
–
Puts
$7K
Net Calls
-$7K
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$701K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$231K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$92.4K
4
BCM
Bridgeway Capital Management
Texas
+$27.6K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$24.6K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$1.08M
2
SSA
Schonfeld Strategic Advisors
New York
-$419K
3
Two Sigma Investments
Two Sigma Investments
New York
-$50.4K
4
Prudential Financial
Prudential Financial
New Jersey
-$12.1K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.41K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$13.2M – – –
MAM
2
MPM Asset Management
Massachusetts
$9.17M – – –
PHS
3
PFM Health Sciences
California
$5.47M +$701K +254,391 +11%
MB
4
MPM BioImpact
Massachusetts
$5.11M – – –
RCMNY
5
Rubric Capital Management (New York)
New York
$4.14M – – –
Bank of America
6
Bank of America
North Carolina
$3.28M +$5.7K +2,069 +0.1%
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$2.14M – – –
SFM
8
Sphera Funds Management
Israel
$1.34M – – –
DF
9
DC Funds
Virginia
$1.26M – – –
Vanguard Group
10
Vanguard Group
Pennsylvania
$1.17M +$231K +83,737 +18%
LCM
11
Laurion Capital Management
New York
$1.12M – – –
Millennium Management
12
Millennium Management
New York
$999K -$1.08M -392,625 -46%
Alyeska Investment Group
13
Alyeska Investment Group
Illinois
$851K – – –
SSA
14
Schonfeld Strategic Advisors
New York
$374K -$419K -151,978 -47%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$373K +$24.6K +8,935 +5%
BCM
16
Bridgeway Capital Management
Texas
$204K +$27.6K +10,000 +12%
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
$167K – – –
BlackRock
18
BlackRock
New York
$165K +$8.63K +3,132 +4%
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$124K +$92.4K +33,515 +136%
State Street
20
State Street
Massachusetts
$109K – – –
Edgewood Management
21
Edgewood Management
Connecticut
$107K – – –
Renaissance Technologies
22
Renaissance Technologies
New York
$97K +$6.34K +2,300 +5%
HSA
23
HBK Sorce Advisory
Pennsylvania
$56.6K – – –
Northern Trust
24
Northern Trust
Illinois
$55.8K – – –
Prudential Financial
25
Prudential Financial
New Jersey
$33K -$12.1K -4,400 -22%
1
2

HOWL Hedge Fund Activity: Q3 2023 in Review

35 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q3 2023, worth a combined $51.1M — down 30% from $73.3M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of HOWL and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 11 added.

The largest buyer was PFM Health Sciences, adding an estimated $701K. The largest seller was Millennium Management, cutting an estimated $1.08M.

  • 35 institutional investors held Werewolf Therapeutics (HOWL) as of Q3 2023, down from 36 in Q2 2023.
  • Funds reported $51.1M of Werewolf Therapeutics stock for Q3 2023, down 30% quarter-over-quarter.
  • 2 funds opened new Werewolf Therapeutics positions in Q3 2023 and 3 closed out, a net change of -1 holder.
  • The largest Werewolf Therapeutics buyer in Q3 2023 was PFM Health Sciences, an estimated $701K added.
  • The largest Werewolf Therapeutics seller in Q3 2023 was Millennium Management, an estimated $1.08M sold.

Based on aggregated 13F filings for Q3 2023.